Fulcrum Therapeutics, Inc. (FULC): Cash & Equivalents
$197.53M
As of 2025-12-31
$48.47M
As of 2026-06-30
+77.9%
3-year compound annual growth
+28.2%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $197.53M | +239.3% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $58.21M | +127.7% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $25.56M | -27.2% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $35.10M | -0.9% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $35.41M | -37.9% | 2023-06-26, Balance as of period end |
| 2020-12-31 | $57.05M | -41.0% | 2023-06-26, Balance as of period end |
| 2019-12-31 | $96.71M | +32.9% | 2023-06-23, Balance as of period end |
| 2018-12-31 | $72.80M | n/a | 2020-03-05, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | 2025-12-31 | $197.53M | +239.3% |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.52B | +11.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $10.21B | -1.3% |
| TherapeuticsMD, Inc. (TXMD) | 2024-12-31 | $5.06M | +16.9% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $7.27B | +122.4% |
| Pfizer Inc (PFE) | 2025-12-31 | $1.14B | +9.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $19.71B | -18.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $93.89M | +10.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $14.56B | +10.0% |
Compare FULC, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗